Sinco Pharmaceutical Holdings (HKSE:06833) EV-to-EBIT : 2.35 (As of May. 15, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sinco Pharmaceutical Holdings's Enterprise Value is HK$282 Mil. Sinco Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$120 Mil. Therefore, Sinco Pharmaceutical Holdings's EV-to-EBIT for today is 2.35.

The historical rank and industry rank for Sinco Pharmaceutical Holdings's EV-to-EBIT or its related term are showing as below:

HKSE:06833' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.91 Med: 5.22 Max: 27.75
Current: 2.32

During the past 10 years, the highest EV-to-EBIT of Sinco Pharmaceutical Holdings was 27.75. The lowest was -8.91. And the median was 5.22.

HKSE:06833's EV-to-EBIT is ranked better than
95.06% of 81 companies
in the Medical Distribution industry
Industry Median: 13.3 vs HKSE:06833: 2.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sinco Pharmaceutical Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$284 Mil. Sinco Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$120 Mil. Sinco Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 42.26%.

Sinco Pharmaceutical Holdings EV-to-EBIT Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings EV-to-EBIT Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

8.39

2.48

14.87

3.06

2.37

Sinco Pharmaceutical Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial														14.87	-	3.06	-	2.37

Competitive Comparison of Sinco Pharmaceutical Holdings's EV-to-EBIT

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinco Pharmaceutical Holdings's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's EV-to-EBIT falls into.

Sinco Pharmaceutical Holdings EV-to-EBIT Calculation

Sinco Pharmaceutical Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	282.151	/	119.975
	=	2.35

Sinco Pharmaceutical Holdings's current Enterprise Value is HK$282 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinco Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$120 Mil.

Sinco Pharmaceutical Holdings (HKSE:06833) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sinco Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	119.975	/	283.8806
	=	42.26 %

Sinco Pharmaceutical Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$284 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinco Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$120 Mil.

Sinco Pharmaceutical Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines